// App-Quantinova.ai

13 : Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52- Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials

Researchers

Presenter

  • Phillip Mease

Principal Investigators

  • Arthur Kavanaugh

  • Randall Stevens

  • Christopher Edwards

  • Charles Birbara

  • Adewale Adebajo

  • Juan Gomez-Reino

  • Jurgen Wollenhaupt

  • Maurizio Cutolo

  • Georg Schett

  • Eric Lespessailles

  • Kamal Shah

  • Chia Chi Hu

Medical Centers

  • Radiology, Schon Klinik Hamburg Eilbek, Hamburg, Germany

  • University of Erlangen-Nuernberg, Erlangen, Germany

  • Toronto Western Hospital, Toronto, ON, Canada

  • Universite dOrleans, Orleans, France

Locations

  • France

  • Germany

  • Canada

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Sulfasalazine

  • Methotrexate

  • HWA-486

  • Apremilast

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved